Baird Financial Group
HRTX icon

Baird Financial Group’s Heron Therapeutics HRTX Stock Holding History

Baird Financial Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-64,155
Closed -$586K – 1866
2021
Q4 		$586K Buy
64,155
+5,820
+10% +$59.4K ﹤0.01% 1414
2021
Q3 		$624K Buy
58,335
+11,527
+25% +$140K ﹤0.01% 1389
2021
Q2 		$726K Buy
+46,808
New +$745K ﹤0.01% 1299
2020
Q2 		– Sell
-11,517
Closed -$135K – 1536
2020
Q1 		$135K Buy
11,517
+2,140
+23% +$40.2K ﹤0.01% 1360
2019
Q4 		$220K Buy
+9,377
New +$207K ﹤0.01% 1439

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Baird Financial Group's HRTX Position: Q1 2022 in Review

Baird Financial Group sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 64,155 shares — an estimated $586K sold.

Baird Financial Group first reported a position in HRTX in Q4 2019 and held it in 5 quarters. The position peaked at $726K in Q2 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

  • Baird Financial Group reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Baird Financial Group sold 64,155 Heron Therapeutics shares in Q1 2022, an estimated $586K.
  • Baird Financial Group first reported a position in Heron Therapeutics in Q4 2019 and held it in 5 quarters.
  • Baird Financial Group's Heron Therapeutics position peaked at $726K in Q2 2021.
  • 186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Baird Financial Group's 13F filing for Q1 2022, filed 13 May 2022.